Delmar Pharmaceuticals, Inc. (DMPI) SEC Filing 8-K Material Event for the period ending Thursday, September 26, 2019

Delmar Pharmaceuticals, Inc.

CIK: 1498382 Ticker: DMPI

View differences made from one to another to evaluate Delmar Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Delmar Pharmaceuticals, Inc..


Assess how Delmar Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Delmar Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


Ticker: DMPI
CIK: 1498382
Form Type: 8-K Corporate News
Accession Number: 0001213900-19-019207
Submitted to the SEC: Fri Sep 27 2019 5:08:38 PM EST
Accepted by the SEC: Fri Sep 27 2019
Period: Thursday, September 26, 2019
Industry: Pharmaceutical Preparations
  1. Listing Status

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: